

CURRICULUM VITAE

Name: Mirosław J. Szczepanski, MD, PhD

Associate Professor

- **Birth Date:** March 25th, 1975
- **Citizenship:** Polish
- **E-mail Address:** mirski1975@gmail.com
- **Correspondence address:** Specjalistyczna Praktyka Lekarska Mirosław Szczepański, ul. Jana Nowaka-Jeziorańskiego 9/U6, 03-984 Warszawa

==

SUMMARY:

Mirosław J. Szczepanski, MD PhD is an actively practicing laryngologist and scientist. He received a residency training in Otolaryngology and Head and Neck Surgery and passed his specialization exam in 2012. His clinical interests relate to endoscopic treatment of chronic rhinosinusitis, Graves' ophthalmopathy and scuba-diving related diseases. He took a number of hands-on cadaver dissection courses mainly in the USA. He received his PhD in tumor immunology in 2010 and completed a 3-year postdoctoral fellowship at the University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. In 2011 he completed a one-month internship at the University of New Mexico in the USA in technology transfer. In 2017 he received a habilitation degree in medicine. His scientific activity focuses on the immunological aspects of chronic inflammation, innate immunity and tumor immunology. He is the author or co-author of more than 50 research or review papers and 1 book chapter on the complications of endoscopic sinus surgery. He received a number of awards for his scientific activity, and his doctoral dissertation received the award of the then Minister of Health in 2011. He was the primary investigator of several research grants obtained through a competition. Privately, his passion is scuba-diving and playing tennis.

==

EDUCATION AND TRAINING

GRADUATE:			
Dates Attended	Name and Location of Institution	Degree Received and Year	Discipline
1995-2001	Poznan University of Medical Sciences, School of Medicine, Poznan, Poland	MD, 2001	Medicine
2010	Poznan University of Medical Sciences, Poznan, Poland	PhD, 2010	Immunology
2017	Medical University of Warsaw, Poland	Habilitation, 2017	Medicine

POST GRADUATE:			
Dates Attended	Name and Location of Institution	Degree Received and Year	Discipline
2004-2012	Department of Otolaryngology, Medical University of Warsaw, Poland/	Residency in Otolaryngology, 2012	Otolaryngology

2006-2009	University of Pittsburgh Cancer Institute, Pittsburgh PA, USA	Postdoctoral fellowship	Immunology
-----------	--	-------------------------	------------

POST GRADUATE TRAININGS:

Dates Attended	Name and Location of Institution	Degree Received and Year	Discipline
2020.01	Functional Endoscopic Sinus Surgery (FESS) Course, Dubai, UAE	“Hands-on” cadaver dissection course	Rhinology
2015.02	Department of Otolaryngology Head & Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA	Visiting fellowship	Rhinology
2013.04	Temporal Bone Surgical Dissection Course, Department of Otolaryngology, Emory University School of Medicine, Atlanta, USA	“Hands-on” cadaver dissection course	Otology
2013.03	PENN Rhinoplasty Course, Department of Otolaryngology, University of Pennsylvania, Philadelphia, USA	“Hands-on” cadaver dissection course	Rhinology
2012.05	Department of Otolaryngology, Division of Sino-Nasal Disorders & Allergy, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA	Visiting fellowship	Rhinology
2012.02	Department of Otolaryngology, General University Hospital, Prague, Czech Republic	Visiting fellowship	Rhinology
2011	University of New Mexico, Albuquerque, NM, USA	Technology Transfer Training	Life Sciences
2011.04	Department of Otolaryngology, Division of Sino-Nasal Disorders & Allergy, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA	Visiting fellowship	Rhinology
2011.03	The PENN International Rhinology and Skull Base Dissection Course, Department of Otolaryngology, University of Pennsylvania, Philadelphia, USA	“Hands-on” cadaver dissection course	Rhinology
2010.11	Advanced Techniques in Endoscopic Management of Sinonasal Disorders, Sinus and Nasal Institute of Florida, St. Petersburg, USA	“Hands-on” cadaver dissection course	Rhinology

APPOINTMENTS and POSITIONS

Years Inclusive	Name and Location of Institution or Organization	Rank/Title
2017-present	Department of Biochemistry, Medical University of Warsaw, Poland	Associate Professor

2012-2016	Department of Otolaryngology, Medical University of Warsaw, Poland	Assistant Professor
2003-2011	Department of Otolaryngology, Poznan University of Medical Sciences, Poznan, Poland	Assistant Professor
2001-2012	Department of Immunology, Poznan University of Medical Sciences, Poznan, Poland	Assistant Professor

List of publications

Books

1. One chapter: Dzaman K, **Szczepanski MJ**: "Complications of endoscopic sinus surgery". Sinus surgery-transnasal endoscopic approach. Krzeski A. (editor), 2015.

Original/Review manuscripts

2021

1. Łacheta D, Poślednik KB, Czerwaty K, Ludwig N, Molińska-Glura M, Kantor I, Jabłońska-Pawlak A, Miśkiewicz P, Głuszko A, Stopa Z, Brzost J, **Szczepański MJ**. RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves' Ophthalmopathy. *Mediators Inflamm*. 2021 Mar 11;2021:8891324.
2. Piszczatowska K, Czerwaty K, Cyran AM, Fiedler M, Ludwig N, Brzost J, **Szczepański MJ**. The Emerging Role of Small Extracellular Vesicles in Inflammatory Airway Diseases. *Diagnostics (Basel)*. 2021 Feb 2;11(2):222.

2020

3. Ludwig N, Rubenich DS, Zaręba Ł, Siewiera J, Pieper J, Braganhol E, Reichert TE, **Szczepański MJ**. Potential Roles of Tumor Cell- and Stroma Cell-Derived Small Extracellular Vesicles in Promoting a Pro-Angiogenic Tumor Microenvironment. *Cancers (Basel)*. 2020 Dec 2;12(12):3599. doi: 10.3390/cancers12123599. PMID: 33276428; PMCID: PMC7760552.

2019

4. Łacheta D, Miśkiewicz P, Głuszko A, Nowicka G, Struga M, Kantor I, Poślednik KB, Mirza S, **Szczepanski MJ (corresponding author)**. Immunological Aspects of Graves' Ophthalmopathy. *Biomed Res Int*. 2019 Nov 12;2019:7453260.
5. Poślednik KB, Miśkiewicz P, Jabłońska-Pawlak A, Kantor I, **Szczepanski MJ (corresponding author)**. Endoscopic decompression of orbit in Graves' orbitopathy. *Pol Merkur Lekarski*. 2019 May 27;46(275):224-228.
6. Głuszko A, **Szczepanski MJ (corresponding author)**, Ludwig N, Mirza SM, Olejarz W. Exosomes in Cancer: Circulating Immune-Related Biomarkers. *Biomed Res Int*. 2019 Dec 11;2019:1628029.
7. Szafarowski T, Sierdziński J, Ludwig N, Głuszko A, Filipowska A, **Szczepanski MJ (corresponding author)**. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1). *Eur J Pharmacol*. 2020 Jan 15;867:172837.
8. Ludwig N, **Szczepanski MJ**, Głuszko A, Szafarowski T, Azambuja JH, Dolg L, Gellrich NC, Kampmann A, Whiteside TL, Zimmerer RM. CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma. *Cancer Lett*. 2019 Dec 28;467:85-95.

2018

9. Cyran AM, Kosla A, Kantor I, **Szczepanski MJ (corresponding author)**. Tympanometric evaluation of Eustachian tube function in Polish scuba divers. *Undersea Hyperb Med*. 2018 Jul-Aug;45(4):437-443. PMID: 30241123.
10. Olejarz W, Łacheta D, Głuszko A, Migacz E, Kukwa W, **Szczepanski MJ**, Tomaszewski P, Nowicka G. RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy. *Biomed Res Int*. 2018 Aug 26;2018:7675286.

11. Szafarowski T, Sierdzinski J, **Szczepanski MJ**, Whiteside TL, Ludwig N, Krzeski A. Microvessel density in head and neck squamous cell carcinoma. *Eur Arch Otorhinolaryngol*. 2018 Jul;275(7):1845-1851.
- 2017**
12. Ostrowska K, Olejarz W, Wrzosek M, Głuszko A, Nowicka G, **Szczepanski MJ**, Materek IB, Koziol AE, Struga M. Anticancer effects of O-aminoalkyl derivatives of alloxanthoxyletin and seselin. *Biomed Pharmacother*. 2017 Nov;95:1412-1424.
- 2016**
13. Whiteside TL, Ferris RL, **Szczepanski MJ**, Tublin M, Kiss J, Johnson R, Johnson JT. Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. *Head Neck*. 2016 Apr;38 Suppl 1(Suppl 1):E494-501.
- 2015**
14. Brzost J, Cyran AM, Waniewska M, **Szczepanski MJ (corresponding author)**. Internal Carotid Artery Aneurysm Mimicking Peritonsillar Abscess. *Case Rep Otolaryngol*. 2015;2015:389298.
15. Dzaman K, **Szczepanski MJ**, Molinska-Glura M, Krzeski A, Zagor M. Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps. *Arch Immunol Ther Exp (Warsz)*. 2015 Jun;63(3):223-30.
16. **Szczepanski MJ**, Luczak M, Olszewska E, Molinska-Glura M, Zagor M, Krzeski A, Skarzynski H, Misiak J, Dzaman K, Bilusiak M, Kopec T, Leszczynska M, Witmanowski H, Whiteside TL. Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis. *J Mol Med (Berl)*. 2015 Mar;93(3):305-14.
- 2014**
17. Szafarowski T, **Szczepanski MJ (corresponding author)**. Cancer stem cells in head and neck squamous cell carcinoma. *Otolaryngol Pol*. 2014 May-Jun;68(3):105-11.
18. Wen Y, Zand B, Ozpolat B, **Szczepanski MJ**, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. *Cell Rep*. 2014 Apr 24;7(2):488-500.
- 2013**
19. **Szczepanski MJ**, Whiteside TL. Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? *Biomark Med*. 2013 Aug;7(4):575-8.
20. Czystowska M, Gooding W, **Szczepanski MJ**, Lopez-Abaitero A, Ferris RL, Johnson JT, Whiteside TL. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. *Clin Cancer Res*. 2013 Feb 15;19(4):889-99.
21. **Szczepanski MJ**, DeLeo AB, Łuczak M, Molinska-Glura M, Misiak J, Szarzynska B, Dworacki G, Zagor M, Rozwadowska N, Kurpisz M, Krzeski A, Kruk-Zagajewska A, Kopec T, Banaszewski J, Whiteside TL. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. *Oral Oncol*. 2013 Feb;49(2):144-51.
- 2012**
22. Mandapathil M, **Szczepanski MJ**, Harasymczuk M, Ren J, Cheng D, Jackson EK, Gorelik E, Johnson J, Lang S, Whiteside TL. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. *Oncoimmunology*. 2012 Aug 1;1(5):659-669.
23. Szajnik M, **Szczepanski MJ**, Elishaev E, Visus C, Lenzner D, Zabel M, Glura M, DeLeo AB, Whiteside TL. 17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma. *Gynecol Oncol*. 2012 Dec;127(3):587-94.
- 2011**
24. Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, **Szczepanski MJ**, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, DeLeo AB, Wang X. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. *Clin Cancer Res*. 2011 Oct 1;17(19):6174-84.
25. **Szczepanski MJ**, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. *Haematologica*. 2011 Sep;96(9):1302-9.
26. Sikora J, Frydrychowicz M, Kaczmarek M, Brzezicha B, Mozer-Lisewska I, **Szczepanski MJ**, Zeromski J. TLR receptors in laryngeal carcinoma - immunophenotypic, molecular and functional studies. *Folia Histochem Cytobiol*. 2010 Dec;48(4):624-31.

27. Visus C, Ito D, Dhir R, **Szczepanski MJ**, Chang YJ, Latimer JJ, Grant SG, DeLeo AB. Identification of Hydroxysteroid (17 β) dehydrogenase type 12 (HSD17B12) as a CD8⁺ T-cell-defined human tumor antigen of human carcinomas. *Cancer Immunol Immunother.* 2011 Jul;60(7):919-29.
28. Whiteside TL, Mandapathil M, **Szczepanski MJ**, Szajnik M. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. *Bull Cancer.* 2011 Feb;98(2):E25-31.
29. Czystowska M, **Szczepanski MJ**, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Whiteside TL. Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. *Cancer Immunol Immunother.* 2011 Apr;60(4):495-506.

2010

30. Szajnik M, Czystowska M, **Szczepanski MJ**, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). *PLoS One.* 2010 Jul 22;5(7):e11469.
31. Mandapathil M, **Szczepanski MJ**, Szajnik M, Ren J, Jackson EK, Johnson JT, Gorelik E, Lang S, Whiteside TL. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. *J Biol Chem.* 2010 Sep 3;285(36):27571-80.
32. Song JJ, **Szczepanski MJ**, Kim SY, Kim JH, An JY, Kwon YT, Alcalá MA Jr, Bartlett DL, Lee YJ. c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. *Cell Signal.* 2010 Mar;22(3):553-63.
33. Mandapathil M, Hilldorfer B, **Szczepanski MJ**, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL. Generation and accumulation of immunosuppressive adenosine by human CD4⁺CD25^{high}FOXP3⁺ regulatory T cells. *J Biol Chem.* 2010 Mar 5;285(10):7176-86.
34. **Szczepanski MJ**, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. *Cancer Immunol Immunother.* 2010 Jan;59(1):73-9.

2009

35. Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, **Szczepanski MJ**, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, Myers EN, Vujanovic NL. Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer. *Cancer Epidemiol Biomarkers Prev.* 2009 Nov;18(11):2913-22.
36. Mandapathil M, **Szczepanski MJ**, Szajnik M, Ren J, Lenzner DE, Jackson EK, Gorelik E, Lang S, Johnson JT, Whiteside TL. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. *Clin Cancer Res.* 2009 Oct 15;15(20):6348-57.
37. Wieckowski EU, Visus C, Szajnik M, **Szczepanski MJ**, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8⁺ T lymphocytes. *J Immunol.* 2009 Sep 15;183(6):3720-30.
38. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, **Szczepanski MJ**, Szajnik ME, Gorelik E, Lokshin AE. Biological significance of prolactin in gynecologic cancers. *Cancer Res.* 2009 Jun 15;69(12):5226-33.
39. **Szczepanski MJ**, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. *Clin Cancer Res.* 2009 May 15;15(10):3325-32.
40. Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, **Szczepanski MJ**, Szajnik ME, Gorelik E, Lokshin AE. Role of eotaxin-1 signaling in ovarian cancer. *Clin Cancer Res.* 2009 Apr 15;15(8):2647-56.
41. **Szczepanski MJ**, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. *Cancer Res.* 2009 Apr 1;69(7):3105-13.

2008

42. Bergmann C, Strauss L, Wang Y, **Szczepanski MJ**, Lang S, Johnson JT, Whiteside TL. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. *Clin Cancer Res.* 2008 Jun 15;14(12):3706-15.
43. Lee DH, **Szczepanski MJ**, Lee YJ. Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. *Biochem Pharmacol.* 2008 Jun 15;75(12):2345-55.
44. Strauss L, Bergmann C, **Szczepanski MJ**, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4⁺CD25^{high}Foxp3⁺ T regulatory cells: implications and impact on tumor-mediated immune suppression. *J Immunol.* 2008 Mar 1;180(5):2967-80.

45. Boyiadzis M, Memon S, Carson J, Allen K, **Szczepanski MJ**, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. *Biol Blood Marrow Transplant*. 2008 Mar;14(3):290-300.

2007

46. Strauss L, Bergmann C, **Szczepanski MJ**, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4⁺CD25^{high}Foxp3⁺ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. *Clin Cancer Res*. 2007 Aug 1;13(15 Pt 1):4345-54.
47. **Szczepanski MJ**, Stelmachowska M, Stryczyński L, Golusiński W, Samara H, Mozer-Lisewska I, Zeromski J. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. *Eur Arch Otorhinolaryngol*. 2007 May;264(5):525-30.

2006

48. **Szczepanski MJ**, Kopeć T, Szyfter W, Zeromski J. The assessment of intravital staining of parotid gland using methylene blue in the surgery of benign gland tumors--preliminary report. *Otolaryngol Pol*. 2006;60(4):513-5. Polish.
49. **Szczepanski MJ** Szyfter W, Jenek R, Wróbel M, Lisewska IM, Zeromski J. Toll- like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma. *Eur Arch Otorhinolaryngol*. 2006 Jul;263(7):603-7.

2005

50. Zeromski J, **Szczepanski MJ**, Mozer-Lisewska. Obecność antygenu CD56/NCAM w układzie nerwowym, odpornościowym i gruczołach dokrewnych—przypadkowa zbiegłość? [Prevalence of CD56 /NCAM molecule in nervous system immune system and endocrine glands--accidental coincidence?] *Endokrynol Pol*. 2005 Jan- Feb;56(1):78-82. Polish.

2004

51. Dworacki G, **Szczepanski MJ**, Kruk-Zagajewska A, Zeromski J. Cytotoxic T lymphocytes in peripheral blood and regional lymph nodes in laryngeal cancer patients. *Otolaryngol Pol*. 2004;58(6):1071-6. Polish.

Clinical and scientific interests:

- endoscopic treatment of chronic rhinosinusitis, Graves' ophthalmopathy, and ENT related scuba-diving diseases
- immunology aspects of chronic sinusitis and Graves' ophthalmopathy, tumor immunology